Michael Babcock, Jianhong Zheng, Li Li, Marvin Garovoy, Yuqiao Shen. Development of AL01211, a novel Glucosylceramide Synthase Inhibitor, to treat Fabry disease. 7th International Update on Fabry Disease, 29–31 May 2022, Würzburg, Germany
Michael Babcock, Jianhong Zheng, Li Li, Marvin Garovoy, Yuqiao Shen. Development of AL01211, a novel Glucosylceramide Synthase Inhibitor, to treat Fabry disease. 7th International Update on Fabry Disease, 29–31 May 2022, Würzburg, Germany
Michael Babcock, Ying Feng, Benjamin Liou, Venette Fannin, Yi Lin, Jerry Shen, Ying Sun. Development of AL00804, a novel brain penetrant glucosylceramide synthase inhibitor, to treat Gaucher disease and other neuronopathic glycosphingolipid storage diseases. World Symposium Feb 22-26 2023, Orlando, Florida
